Inside Precision Medicine·4 min read·hard
Predicting Drug Response with Lung Cancer Tumor Replica Platform
A
Alisa Kirkin
✦AI Summary
A new study introduces an ex vivo platform that uses 3D lung tumor replicas to test drug responses directly, aiming to improve precision oncology. This method seeks to overcome the limitations of genomic profiling by providing functional testing for personalized treatment.
Precision oncology has transformed lung cancer care, but its reach remains uneven. Targeted therapies and immunotherapies have improved outcomes for selected patients, yet many people with lung cancer still receive systemic treatment without a reliable way to know whether their tumor will respond.
healthsciencetechnology
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in